|
Safety and effectiveness of regorafenib (REG) in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: An interim analysis (IA) from the prospective, observational CORRELATE study. |
|
|
Honoraria - Lilly; Servier |
Consulting or Advisory Role - Amgen; Celgene; Ipsen; Lilly; Merck Serono; Novartis; Roche; Servier |
Speakers' Bureau - Bayer; Celgene; Ipsen; Merck KGaA; Roche |
Research Funding - Pfizer; Roche |
Travel, Accommodations, Expenses - Celgene; Ipsen; Merck Serono; Roche |
Other Relationship - Sandoz (I) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Merck; MSD; Roche |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bayer; Lilly; Merck; Roche; Sanofi; SERVIER |
Consulting or Advisory Role - Amgen; Bayer; Lilly; Merck; Roche; Sanofi; SERVIER |
Research Funding - Amgen; Bayer; Lilly; Merck; Roche; Sanofi; SERVIER |
|
|
Consulting or Advisory Role - Amgen; Bayer; Merck Serono; Nordic Bioscience; Roche |
|
|
|
|
|
|
Stock and Other Ownership Interests - Bayer |
|
Andres Cervantes-Ruiperez |
Consulting or Advisory Role - Amgen; Bayer; Lilly; Merck Serono; Roche/Genentech |
Speakers' Bureau - Merck Serono; Roche |
|
|
Consulting or Advisory Role - Bayer; Lilly; Merck Serono; Raffo |